Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$8.32 -0.6%	$8.89	$3.51 ▼ $14.44	$710.30M	0.82	1.22 million shs	652,997 shs
NAGE Niagen Bioscience	$10.95 +4.3%	$7.59	$2.31 ▼ $10.99	$862.53M	1.94	842,541 shs	1.05 million shs
VIR Vir Biotechnology	$4.60 +1.1%	$5.97	$4.32 ▼ $14.45	$635.90M	1.36	1.37 million shs	1.31 million shs
VYGR Voyager Therapeutics	$3.30 +0.6%	$3.43	$2.75 ▼ $9.55	$182.61M	0.95	443,313 shs	365,716 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	0.00%	+0.85%	-7.04%	-2.35%	+85.30%
NAGE Niagen Bioscience	0.00%	+22.35%	+61.98%	+86.54%	+220.18%
VIR Vir Biotechnology	0.00%	-9.63%	-16.36%	-52.33%	-54.09%
VYGR Voyager Therapeutics	0.00%	+1.85%	+4.43%	-21.99%	-61.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.9374 of 5 stars	3.7	1.0	0.0	4.7	3.2	0.8	0.6
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	2.7673 of 5 stars	3.4	1.0	0.0	0.0	2.5	3.3	1.3
VYGR Voyager Therapeutics	4.6141 of 5 stars	4.6	1.0	0.0	4.6	2.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.33	Buy	$44.00	428.85% Upside
NAGE Niagen Bioscience	0.00	N/A	N/A	N/A
VIR Vir Biotechnology	2.86	Moderate Buy	$32.86	614.29% Upside
VYGR Voyager Therapeutics	3.13	Buy	$13.39	305.76% Upside

Current Analyst Ratings Breakdown

Latest VYGR, NAGE, VIR, and AVXL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$19.00 ➝ $14.00
4/17/2025	VIR Vir Biotechnology	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $21.00
4/8/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/7/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
4/7/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
3/31/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
3/13/2025	VYGR Voyager Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
3/13/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/12/2025	VYGR Voyager Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$12.00 ➝ $10.00
3/12/2025	VYGR Voyager Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
3/12/2025	VYGR Voyager Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight

(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
NAGE Niagen Bioscience	$107.93M	7.99	N/A	N/A	N/A	∞
VIR Vir Biotechnology	$14.30M	44.46	N/A	N/A	$11.82 per share	0.39
VYGR Voyager Therapeutics	$66.96M	2.73	$2.34 per share	1.41	$5.37 per share	0.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-37.50%	-34.08%	8/5/2025 (Estimated)
NAGE Niagen Bioscience	N/A	$0.17	64.41	∞	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	-$615.06M	-$4.22	N/A	N/A	N/A	-678.40%	-36.71%	-31.00%	7/30/2025 (Estimated)
VYGR Voyager Therapeutics	$132.33M	-$1.46	4.65	N/A	N/A	15.80%	8.33%	6.15%	8/5/2025 (Estimated)

Latest VYGR, NAGE, VIR, and AVXL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/7/2025	Q1 2025	VIR Vir Biotechnology	-$0.83	-$0.88	-$0.05	-$0.88	$8.59 million	$3.03 million
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million
3/11/2025	Q4 2024	VYGR Voyager Therapeutics	-$0.35	-$0.59	-$0.24	-$0.59	$16.58 million	$4.39 million
2/26/2025	Q4 2024	VIR Vir Biotechnology	-$0.85	-$0.76	+$0.09	-$0.76	$8.14 million	$12.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	9.45	9.45
NAGE Niagen Bioscience	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	8.94	8.94
VYGR Voyager Therapeutics	N/A	8.45	8.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
NAGE Niagen Bioscience	15.41%
VIR Vir Biotechnology	65.32%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.40%
NAGE Niagen Bioscience	9.39%
VIR Vir Biotechnology	15.60%
VYGR Voyager Therapeutics	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.37 million	75.71 million	Optionable
NAGE Niagen Bioscience	120	78.77 million	N/A	N/A
VIR Vir Biotechnology	580	138.24 million	116.24 million	Optionable
VYGR Voyager Therapeutics	100	55.34 million	52.15 million	Optionable

VYGR, NAGE, VIR, and AVXL Headlines

Recent News About These Companies

Voyager reports breakthrough in brain drug delivery

May 17 at 9:49 PM | uk.investing.com

Voyager Therapeutics Publishes Data on ALPL's Role in AAV Transport Across the Blood-Brain Barrier

May 15 at 7:26 AM | quiverquant.com

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

May 15 at 7:00 AM | globenewswire.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stake Decreased by Bridgeway Capital Management LLC

May 15 at 4:15 AM | marketbeat.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock Position Increased by Dimensional Fund Advisors LP

May 13, 2025 | marketbeat.com

Q2 EPS Forecast for Voyager Therapeutics Reduced by Analyst

May 13, 2025 | marketbeat.com

What is Leerink Partnrs' Forecast for VYGR Q2 Earnings?

May 11, 2025 | marketbeat.com

Wedbush Equities Analysts Boost Earnings Estimates for VYGR

May 11, 2025 | marketbeat.com

Farallon Capital Management LLC Has $14.58 Million Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

May 11, 2025 | marketbeat.com

FY2025 EPS Estimates for VYGR Raised by Cantor Fitzgerald

May 11, 2025 | americanbankingnews.com

Q2 Earnings Estimate for VYGR Issued By Leerink Partnrs

May 11, 2025 | americanbankingnews.com

Wedbush Issues Optimistic Forecast for VYGR Earnings

May 11, 2025 | americanbankingnews.com

What is Leerink Partnrs' Forecast for VYGR FY2029 Earnings?

May 10, 2025 | marketbeat.com

Voyager Therapeutics, Inc.: Voyager Reports First Quarter 2025 Financial and Operating Results

May 9, 2025 | finanznachrichten.de

Analysts Set Expectations for VYGR FY2029 Earnings

May 9, 2025 | americanbankingnews.com

Raymond James Financial Inc. Takes $746,000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

May 9, 2025 | marketbeat.com

Neurocrine hands back 2 CNS gene therapy programs to Voyager

May 7, 2025 | fiercebiotech.com

Voyager Therapeutics (VYGR) Expected to Announce Quarterly Earnings on Monday

May 7, 2025 | marketbeat.com

Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates

May 6, 2025 | zacks.com

Voyager Reports First Quarter 2025 Financial and Operating Results

May 6, 2025 | globenewswire.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Renaissance Technologies LLC

May 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warning or Opportunity After Super Micro Computer's Earnings
By Gabriel Osorio-Mazilli | May 5, 2025
View Warning or Opportunity After Super Micro Computer's Earnings
3 Alternative Asset Managers Are Raising Dividends by 5% to 25%
By Leo Miller | May 13, 2025
View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%
3 Stocks to Buy Now for Tariff Immunity
By Gabriel Osorio-Mazilli | April 23, 2025
View 3 Stocks to Buy Now for Tariff Immunity
Medtronic: A Dividend Aristocrat With Stability and Innovation
By Jeffrey Neal Johnson | April 22, 2025
View Medtronic: A Dividend Aristocrat With Stability and Innovation
Waste Management Stock: Tariff Proof, But Overbought?
By Chris Markoch | May 2, 2025
View Waste Management Stock: Tariff Proof, But Overbought?

VYGR, NAGE, VIR, and AVXL Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$8.32 -0.05 (-0.60%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$8.33 +0.01 (+0.12%)

As of 05/16/2025 07:15 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Niagen Bioscience NASDAQ:NAGE

$10.95 +0.45 (+4.29%)

As of 05/16/2025 04:00 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Vir Biotechnology NASDAQ:VIR

$4.60 +0.05 (+1.10%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$4.54 -0.06 (-1.30%)

As of 05/16/2025 07:44 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Voyager Therapeutics NASDAQ:VYGR

$3.30 +0.02 (+0.61%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$3.39 +0.09 (+2.73%)

As of 05/16/2025 07:38 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time